Wave Life Sciences错过第三季度报告

2025-11-10 20:42

Wave Life Sciences press release (WVE): Q3 GAAP EPS of -$0.32 misses by $0.01.
Revenue of $7.61M (+-199.1% Y/Y) misses by $2.92M.
Cash and cash equivalents were $196.2 million as of September 30, 2025, compared to $302.1 million as of December 31, 2024.

More on Wave Life Sciences

Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics - Slideshow
Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript
Wave Life Sciences Q3 2025 Earnings Preview
Wave Life Sciences drops after trial data for GSK-partnered RNA-editing therapy